Utility of EORTC and CUETO Scoring Models in the Estimation of Recurrence and Progression of Non-Muscle-Invasive Bladder Cancer
Objectives: Worldwide, Non-Muscle-Invasive Bladder Cancer (NMIBC) patients are characterized by a high rate of recurrence and progression highlighting the need for a valuable prognostic estimation for better management of this disease. Thus, the present preliminary study was planned to evaluate the validation of the European Organization for Research and Treatment of Cancer (EORTC) and the Spanish Urological Club for Oncological Treatment (CUETO) risk tables to predict recurrence and progression in Moroccan patients with NMIBC.
Methods: A total of 56 NMIBC patients that have undergone transurethral resection of bladder tumor (TURBT), between January 2017 and May 2021, were recruited. The recurrence and progression rates at 1 and 5 years were calculated for each patient using EORTC and CUETO scoring models and compared to EORTC and CUETO risk tables. KaplanMeier was performed to validate stratification and difference between the four groups obtained. A univariate analysis using the Cox regression test was realized to evaluate the association between prognostic factors with recurrence and progression of the disease.
Results: For the 56 NMIBC patients, the median follow-up duration was 49.68 months. In this cohort, 43 patients had recurrent tumors, and 27 showed progression to an advanced stage and/or grade. At 1-year progression and recurrence rates were higher than the values predicted by the EORTC and CUETO risk tables, while both tables overestimate the long-term risk probabilities of recurrence and progression. Only the CUETO model successfully stratified our patients with statistically significant differences between the four groups of recurrence (p=0.005). Of particular interest, univariate Cox analysis indicated that only prior recurrence rate had a significant effect on both recurrence-free survival (p=0.04) and progression-free survival (p=0.037).
Conclusion: CUETO scoring model is better than EORTC for recurrence stratification in Moroccan patients with NMIBC. Both models overestimate risk in 1-year and underestimate risk in 5-years. A prospective study should be
realized in large cohorts to establish an ideal prognosis model for Moroccan NMIBC patients.
1. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA A Cancer J Clin. 2021;71:209–49. [CrossRef]
2. Cumberbatch MGK, Jubber I, Black PC, Esperto F, Figueroa JD, Kamat AM, et al. Epidemiology of bladder cancer: a systematic review and contemporary update of risk factors in 2018. Eur Urol 2018;74:784–95. [CrossRef]
3. Greene FL, Balch CM, Fleming ID, Fritz A, Haller DG, Morrow M, et al. AJCC cancer staging handbook: TNM classification of malignant tumors. New York: Springer Science & Business Media; 2002. [CrossRef]
4. Anastasiadis A, de Reijke TM. Best practice in the treatment of nonmuscle invasive bladder cancer. Ther Adv Urol 2012;4:13– 32. [CrossRef]
5. Sylvester RJ, Rodríguez O, Hernández V, Turturica D, Bauerová L, Bruins HM, et al. European Association of Urology (EAU) prognostic factor risk groups for non-muscle-invasive bladder cancer (NMIBC) incorporating the WHO 2004/2016 and WHO 1973 classification systems for grade: an update from the EAU NMIBC guidelines panel. Eur Urol 2021;79:480– 8. [CrossRef]
6. Sylvester RJ, van der Meijden APM, Oosterlinck W, Witjes JA, Bouffioux C, Denis L, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006;49:466–5; discussion 475–7.
7. Fernandez-Gomez J, Madero R, Solsona E, Unda M, Martinez-Piñeiro L, Gonzalez M, et al. Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model. J Urol 2009;182:2195–203. [CrossRef]
8. Fahmy N, Lazo-Langner A, Iansavichene AE, Pautler SE. Effect of anticoagulants and antiplatelet agents on the efficacy of intravesical BCG treatment of bladder cancer: A systematic review. Can Urol Assoc J 2013;7:E740–9. [CrossRef]
9. Xu T, Zhu Z, Zhang X, Wang X, Zhong S, Zhang M, et al. Predicting recurrence and progression in Chinese patients with nonmuscle-invasive bladder cancer using EORTC and CUETO scoring models. Urology 2013;82:387–93.
10. Vedder MM, Márquez M, de Bekker-Grob EW, Calle ML, Dyrskjøt L, Kogevinas M, et al. Risk prediction scores for recurrence and progression of non-muscle invasive bladder cancer: an international validation in primary tumours. PLoS One 2014;9:e96849. [CrossRef]
11. Gontero P, Sylvester R, Pisano F, Joniau S, Vander Eeckt K, Serretta V, et al. Prognostic factors and risk groups in T1G3 non-muscle-invasive bladder cancer patients initially treated with Bacillus Calmette-Guérin: results of a retrospective multicenter study of 2451 patients. Eur Urol 2015;67:74–82.
12. Garg M. Urothelial cancer stem cells and epithelial plasticity: current concepts and therapeutic implications in bladder cancer. Cancer Metastasis Rev 2015;34:691–701. [CrossRef]
13. Dovey Z, Pfail J, Martini A, Steineck G, Dey L, Renström L, et al. Bladder Cancer (NMIBC) in a population-based cohort from Stockholm County with long-term follow-up; A comparative analysis of prediction models for recurrence and progression, including external validation of the updated 2021 E.A.U. model. Urol Oncol 2022;40:106.e1–106.e10. [CrossRef]
14. Holz S, Albisinni S, Gilsoul J, Pirson M, Duthie V, Quackels T, et al. Risk factor assessment in high-risk, bacillus CalmetteGuérin-treated, non-muscle-invasive bladder cancer. Res Rep Urol 2017;9:195–202.
15. Busato Júnior WFS, Almeida GL, Ribas CAPM, Ribas Filho JM, De Cobelli O. EORTC risk model to predict progression in patients with non–muscle-ınvasive bladder cancer: is it safe to use in clinical practice? Clinical Genitourinary Cancer 2016;14:176–82. [CrossRef]
16. Almeida GL, Busato WF Jr, Ribas CM, Ribas JM Filho, De Cobelli O. External validation of EORTC risk scores to predict recurrence after transurethral resection of brazilian patients with non -muscle invasive bladder cancer stages Ta and T1. Int Braz J Urol 2016;42:932–41. [CrossRef]
17. van Rhijn BWG, Zuiverloon TCM, Vis AN, Radvanyi F, van Leenders GJLH, Ooms BCM, et al. Molecular grade (FGFR3/ MIB-1) and EORTC risk scores are predictive in primary non-muscle-invasive bladder cancer. Eur Urol 2010;58:433–41.
18. Altieri VM, Castellucci R, Palumbo P, Verratti V, Sut M, Olivieri R, et al. Recurrence and progression in non-muscle-invasive bladder cancer using EORTC risk tables. Urol Int 2012;89:61–6.
19. Dalkilic A, Bayar G, Kilinc MF. A comparison of EORTC and CUETO risk tables in terms of the prediction of recurrence and progression in all non-muscle-ınvasive bladder cancer patients. Urol J 2019;16:37–43.
20. Chung JW, Kim JW, Lee EH, Chun SY, Park DJ, Byeon KH, et al. Prognostic significance of the neutrophil-to-lymphocyte ratio in patients with non-muscle ınvasive bladder cancer treated with ıntravesical bacillus calmette-guérin and the relationship with the CUETO scoring model. Urol J. 2021 Oct 16. Doi: 10.22037/uj.v18i.6765. [Epub ahead of print].
21. Zhang G, Steinbach D, Grimm MO, Horstmann M. Utility of the EORTC risk tables and CUETO scoring model for predicting recurrence and progression in non-muscle-invasive bladder cancer patients treated with routine second transurethral resection. World J Urol 2019;37:2699–705. [CrossRef]